ClinicalTrials.gg
CompletedNCT05831449Updated Apr 30, 2026

CPL-01 in the Management of Postoperative Pain After Bunionectomy

A Phase 3 interventional study of Local anesthetic injection of CPL-01 and Naropin, 0.5% Injectable Solution in Bunion and Post-operative Pain, sponsored by Cali Pharmaceuticals LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Cali Pharmaceuticals LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.
Phase
Phase 3
Study type
Interventional
Enrollment
616
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Subjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.

Read the detailed description

After signing informed consent, subjects will be randomly assigned to receive study drug (either Investigational product, positive control, or negative control) during unilateral distal bunionectomy with osteotomy. Subjects will then remain at the hospital for 72-hours where pain and rescue medication usage will be assessed. Follow-up will then occur at 7 and 30 days afterwards.

The hypothesis is that subjects who receive CPL-01 will have less pain and require fewer opioids than subjects in the other two arms.

02

Conditions studied

  • Bunion
  • Post-operative Pain
03

In context

Bunion

58 studies on the registry are indexed under Bunion; 5 are open to participants now.

This study's enrollment of 616 is above the median of 100 across 47 interventional studies indexed under Bunion.

Browse Bunion studies →

Lead sponsor

Cali Pharmaceuticals LLC is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to sign ICF
  • Bunion for elective primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia, without collateral procedures or additional surgeries
  • ≤ 39 kg/m2
  • If biologically female, not pregnant or planning to become pregnant over the study
  • If biologically male, either sterile or using acceptable form of
  • Be willing and able to complete study procedures

Exclusion criteria

Exclusion Criteria:

  • Has previously undergone unilateral simple bunionectomy.
  • Has a planned concurrent surgical procedure
  • Has a concurrent painful condition that may require analgesic treatment during the study period or may confound postsurgical pain assessments
  • Has a history or clinical manifestation of significant medical, neuropsychiatric, or other condition that could preclude or impair study participation or interfere with study assessments.
  • Has a history of malignant hyperthermia or glucose-6-phosphate dehydrogenase deficiency.
  • Has history or evidence of impaired liver function (e.g., [ALT] > 3 × [ULN] or total > 2 × ULN), active hepatic disease, or cirrhosis.
  • Has history or evidence of impaired renal function (e.g., creatinine > 1.5 × ULN).
  • Has a history of in the past year
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
616 participants (actual)

Study arms

  • Experimental
    CPL-01

    Local infiltration of study drug

    Drug: Local anesthetic injection of CPL-01 · Drug: Morphine rescue medication · Drug: Acetaminophen rescue medication · Drug: Oxycodone rescue medication · Procedure: Bunionectomy

  • Active comparator
    Ropivacaine HCl

    Local infiltration of study drug

    Drug: Naropin, 0.5% Injectable Solution · Drug: Morphine rescue medication · Drug: Acetaminophen rescue medication · Drug: Oxycodone rescue medication · Procedure: Bunionectomy

  • Placebo comparator
    Placebo

    Local infiltration of study drug

    Drug: Placebo · Drug: Morphine rescue medication · Drug: Acetaminophen rescue medication · Drug: Oxycodone rescue medication · Procedure: Bunionectomy

Interventions

  • Local anesthetic injection (CPL-01)

    Also known as: CPL-01, Long-acting ropivacaine

  • Local anesthetic injection (positive control \[Naropin\])

    Also known as: ropivacaine HCl

  • DrugPlacebo

    Local anesthetic injection (negative control \[saline placebo\])

    Also known as: Saline placebo

  • DrugMorphine rescue medication

    Rescue opioid (IV morphine) allowed if requested

    Also known as: Opioids (intravenous [IV] morphine)

  • DrugAcetaminophen rescue medication

    Rescue non-opioid (oral acetaminophen) allowed if requested

    Also known as: Non-opioid oral acetaminophen

  • DrugOxycodone rescue medication

    Rescue opioid (PO oxycodone) allowed if requested

    Also known as: Opioids (oral [PO] oxycodone)

  • ProcedureBunionectomy

    Operative bunion repair

    Also known as: Bunion repair

06

What researchers measure

Primary outcomes

  1. Cumulative Pain Score

    Area Under the Curve of the Numeric Rating Scale Score for Pain with Activity. Activity is resting the operative foot with the ball on the floor. Pain Score spans from 0 to 10, where 0 is no pain and 10 is worst pain imaginable.

    Time frame: 72 hours

07

Study locations

1 site
  • Todd Bertoch
    Salt Lake City, Utah 84101, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Sep 2025, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 26, 2023
StartActual
May 22, 2023
Primary completionActual
Sep 25, 2025
CompletionActual
Oct 6, 2025
Results delay requested
Apr 1, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05831449
Lead sponsor
Cali Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
May 22, 2023
Primary completion
Sep 25, 2025
Completion
Oct 6, 2025
Last update
Apr 30, 2026

Study contacts

Erol Onel
study director · Cali Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPL-01

Start the discussion